9/3/2013

The U.S. FDA is working to ensure that all pharmaceutical imports are safe, effective and of the highest quality, and is not targeting Indian companies for tougher treatment than other firms, said Altaf A. Lal, director of the agency's India office. He noted that of four recent deficiency notices, two were for Indian companies, one was American and the other German. The FDA has 12 inspectors -- soon, 19 -- who are based in New Delhi and Mumbai.

Related Summaries